Inspire Advisors LLC Purchases 114 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Inspire Advisors LLC raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,355 shares of the company’s stock after purchasing an additional 114 shares during the period. Inspire Advisors LLC’s holdings in IDEXX Laboratories were worth $569,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Golden State Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 3,766.7% in the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock worth $49,000 after acquiring an additional 113 shares during the period. Sagespring Wealth Partners LLC bought a new position in shares of IDEXX Laboratories in the first quarter worth $229,000. Banque Transatlantique SA bought a new position in shares of IDEXX Laboratories in the fourth quarter worth $2,681,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of IDEXX Laboratories by 13.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company’s stock worth $10,731,000 after acquiring an additional 2,931 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of IDEXX Laboratories by 42.7% in the first quarter. GAMMA Investing LLC now owns 2,187 shares of the company’s stock worth $918,000 after acquiring an additional 654 shares during the period. 87.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the firm’s stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares in the company, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Trading Up 2.8%

Shares of IDXX stock opened at $565.19 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $568.47. The company has a market capitalization of $45.45 billion, a PE ratio of 52.24, a price-to-earnings-growth ratio of 4.11 and a beta of 1.54. The business’s fifty day moving average is $526.59 and its 200 day moving average is $467.41.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. During the same quarter last year, the business posted $2.71 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Leerink Partners raised their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Stifel Nicolaus raised their price target on IDEXX Laboratories from $510.00 to $540.00 and gave the stock a “hold” rating in a report on Wednesday, July 2nd. Morgan Stanley raised their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a report on Monday, May 5th. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, July 12th. Finally, Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $557.88.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.